Latest Health News
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic…
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
BEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE:…
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
September 07, 2025 18:25 ET | Source: Dianthus Therapeutics, Inc. NEW YORK…
KFSHRC to Partake Tomorrow as Strategic Partner in C3 Davos of Healthcare New York Summit
NEW YORK, Sept. 07, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital…
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
September 06, 2025 14:30 ET | Source: BridgeBio Pharma, Inc. - 80%…
Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community
SAN FRANCISCO, Sept. 06, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, Troper…
CERNs FPGA Failure and the Suppression of 3D-Flow and 3D-CBS: A Call to Save Millions of Lives and Billions of Euros
After decades of outreach and evidence—never refuted—it is urgent to fund two…
RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance…
Revive Therapeutics Announces Extension of Proposed Private Placement
TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or…
